Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
Clinical trial NCT04736589 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT04736589
- Sponsor
- Peking Union Medical College
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-02
- Primary completion
- 2024-02-02
- Enrollment
- 270
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.